Press Releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
June 8, 2020•Clinical trial expanded to patients treated with both noninvasive and mechanical ventilation in critical COVID-19
GENEVA and RADNOR, Pa., June 08, 2020 (GLOBE NEWSWIRE) -- RELIEF THERAPEUTICS Holding AG (SIX:RLF) “Relief” and its U.S. partner, NeuroRx, Inc. today announced that the Phase 2/3 clinical...
-
June 1, 2020•First participants treated at the University of Miami Miller School of Medicine with intravenous RLF-100
MIAMI, June 01, 2020 (GLOBE NEWSWIRE) -- RELIEF THERAPEUTICS Holding AG (SIX:RLF) (Relief) and its U.S. partner, NeuroRx, Inc. today announced treatment of the first patients with RLF-100 at the...
-
May 14, 2020•Study to enroll 144 patients with COVID-19 who have progressed to Acute Respiratory Distress and require intensive care with mechanical ventilation
GENEVA and RADNOR, Pa., May 14, 2020 (GLOBE NEWSWIRE) -- RELIEF THERAPEUTICS Holding AG (SIX:RLF) (Relief) and its U.S. partner, NeuroRx, Inc. announced today that NeuroRx has completed final...
-
March 26, 2020Aviptadil is a patented synthetic form of Vasoactive Intestinal Polypeptide that has previously shown promise in treating ARDS
RELIEF THERAPEUTICS Holding AG (SIX: RLF) "Relief", together with NeuroRx, a Delaware Corporation. have filed an Investigational New Drug (IND) Application with the US FDA for a phase 2 trial of...
-
March 25, 2020NeuroRx is leading US development of RLF-100 (Aviptadil) on behalf of Relief Therapeutics' (RLF)
WILMINGTON, DE and RADNOR, PA March 25, 2020 / NeuroRx, a clinical stage biopharma company focused on development of CNS drugs, today announced an expansion of scope to include the co-development...
-
February 10, 2020
NeuroRx will update investors at the upcoming BIO CEO conference on Monday, February 10, 2020 at 10:15am. The company's CEO, Dr. Jonathan Javitt will be presenting an overview of recent results...
-
January 8, 2020Company to attend upcoming JP Morgan Healthcare Conference
NeuroRx, Inc announced that it has received a notice of patent allowance covering the Composition of Matter for its drug NRX-101, which targets suicidal bipolar depression, an unmet medical need...
-
November 12, 2019Conducting Phase 3 trial for NRX-101, an FDA-designated Breakthrough Therapy for Suicidal Bipolar Depression
WILMINGTON, DE - November 12, 2019 / NeuroRx, Inc. (NeuroRx) a clinical stage biopharma company focused on development of drugs targeting depression and suicidality, announced today that it will...
-
October 23, 2019
NeuroRx, Inc (NeuroRx) announced that it has signed an agreement with GEM Global Yield LLC SCS ("GEM"), the New York based private alternative investment group to provide the NeuroRx with up to...
-
September 9, 2019
NeuroRX, a phase 3 biopharma company focused on development of NRX-101, an FDA-designated Breakthrough Therapy for Severe Bipolar Depression with Acute Suicidal Ideation, will present a corporate...
Click here to view our corporate presentation or on the image below